<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="case-report" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Hematol</journal-id><journal-id journal-id-type="iso-abbrev">Ann Hematol</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Annals of Hematology</journal-title></journal-title-group><issn pub-type="ppub">0939-5555</issn><issn pub-type="epub">1432-0584</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12619769</article-id><article-id pub-id-type="pmcid-ver">PMC12619769.1</article-id><article-id pub-id-type="pmcaid">12619769</article-id><article-id pub-id-type="pmcaiid">12619769</article-id><article-id pub-id-type="pmid">40970922</article-id><article-id pub-id-type="doi">10.1007/s00277-025-06607-4</article-id><article-id pub-id-type="publisher-id">6607</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>The diagnosis and clinical characterization of -&#945;3.7/--SEA thalassemia patients: two cases report</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Wang</surname><given-names initials="X">Xiuling</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Ding</surname><given-names initials="Y">Yu</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Huang</surname><given-names initials="Z">Zhiyong</given-names></name><address><email>99222012@qq.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Huang</surname><given-names initials="J">Jin</given-names></name><address><email>sanzai15@163.com</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00p991c53</institution-id><institution-id institution-id-type="GRID">grid.33199.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 7223</institution-id><institution>Department of Medical Laboratory, </institution><institution>The Central Hospital of Wuhan, Huazhong University of Science and Technology, </institution></institution-wrap>Wuhan, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00p991c53</institution-id><institution-id institution-id-type="GRID">grid.33199.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 0368 7223</institution-id><institution>Key Laboratory for Molecular Diagnosis of Hubei Province, Tongji Medical College, </institution><institution>The Central Hospital of Wuhan, Huazhong University of Science and Technology, </institution></institution-wrap>Wuhan, China </aff><aff id="Aff3"><label>3</label>26 Shengli Street, Jianghan District, Wuhan City, Hubei Province China </aff></contrib-group><pub-date pub-type="epub"><day>19</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>104</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">500690</issue-id><fpage>5501</fpage><lpage>5506</lpage><history><date date-type="received"><day>18</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>17</day><month>11</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-11-17 00:25:12.540"><day>17</day><month>11</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="277_2025_Article_6607.pdf"/><abstract id="Abs1"><p id="Par1">&#945;-thalassemia is a hereditary hemolytic anemia, in which the clinical manifestations vary greatly depending on the degree of &#945;-globin gene deletion. -&#945;3.7/--SEA thalassemia is an intermediate type of &#945;-thalassemia, with three &#945;-globin genes deletion. The clinical symptoms of -&#945;3.7/--SEA thalassemia vary from mild to moderate anemia [<xref ref-type="bibr" rid="CR1">1</xref>]. However, little studies had reported the diagnosis and clinical symptoms of -&#945;3.7/--SEA thalassemia. Here we reported two cases of -&#945;3.7/--SEA thalassemia, one inpatient for chronic headache and one outpatient for elevated bilirubin. Two patients were first subjected to blood test, and the laboratory data showed the decreased hemoglobin concentration and mean corpuscular volume. Peripheral blood cells smear displayed that the mature red blood cells were markedly different in size, with enlarged central pale area, occasional oval red blood cells, suggesting the potential microcytic hypochromic anemia. Hemoglobin electrophoresis displayed the low level of HbA2, indicating the &#945;-thalassemia or &#948;-thalassemia. Reverse dot blot hybridization&#8194;assay detected the deletion of &#945;-globin genes in the two cases. After ameliorative treatment for anemia, the inpatient&#8217;s headache was significantly relieved and stable. Comprehensive judgment of clinical symptoms and laboratory test results is applicative for -&#945;3.7/--SEA thalassemia diagnosis. -&#945;3.7/--SEA thalassemia may lead to individual differences in clinical symptoms and complications, which requires more attention and early treatment.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s00277-025-06607-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>&#945;-thalassemia</kwd><kwd>&#945;3.7</kwd><kwd>SEA</kwd><kwd>Globin</kwd><kwd>HbH disease</kwd></kwd-group><funding-group><award-group><funding-source><institution>Natural Science Foundation of China</institution></funding-source><award-id>82200922</award-id><principal-award-recipient><name name-style="western"><surname>Wang</surname><given-names>Xiuling</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Thalassemia, also known as globin dysplasia anemia, is a group of hereditary and hemolytic anemia diseases [<xref ref-type="bibr" rid="CR2">2</xref>], characterized by hemoglobin synthesis defection [<xref ref-type="bibr" rid="CR3">3</xref>]. Thalassemia is prevalent in Mediterranean, African, and Southeast Asian, with an estimated carrier number of over 270&#160;million people worldwide. More than 300 000 children are born each year with either the thalassemia syndrome or one of the structural hemoglobin variants.</p><p id="Par3">According to the type of globin chain deficiency, thalassemia can be divided into two main subcategories, &#945;-thalassemia and &#946;-thalassemia [<xref ref-type="bibr" rid="CR4">4</xref>]. &#945;-thalassemia is caused by a deletion or defect in the &#945;-globin gene, with reduction or absence of synthesis of &#945;-globin chain. Deletional &#945;-thalassemia is characterized by three common deletion mutations in the &#945;-globin gene cluster, including &#945;3.7, &#945;4.2 and SEA. &#945;3.7 thalassemia lacks one globin gene and is considered as a mild form of thalassemia, in which carriers generally have no evident clinical symptoms. SEA thalassemia, also known as Southeast Asian thalassemia, involves the deletion of two &#945;-globin genes. Carriers typically exhibit the phenotype of thalassemia minor.</p><p id="Par4">HbH disease is a predominant subtype of intermediate &#945;-thalassemia, characterized by the deletion of three &#945;-globin genes [<xref ref-type="bibr" rid="CR5">5</xref>]. -&#945;3.7/--SEA thalassemia represents a prototypical form of HbH disease, which is commonly found in southern China, with a detection proportion of 5.5% in a children study [<xref ref-type="bibr" rid="CR6">6</xref>]. The clinical manifestation of -&#945;3.7/--SEA thalassemia is usually a compensatory hemolytic anemia and highly variable depend on the severity of the disease. Mild thalassemia generally have no symptoms, while severe thalassemia may experience symptoms such as pale skin, generalized edema, nausea, vomiting, dizziness and headache, some carriers may also experience abdominal pain, diarrhea, weight loss. Additionally, thalassemia is usually associated with several complications, such as a high risk of thrombosis caused by hypercoagulable state.</p><p id="Par5">In view of the individual variation of -&#945;3.7/--SEA thalassemia, it will make sense to pay more attention on the clinical feature. However, little cases regarding to the clinical symptoms and complication in -&#945;3.7/--SEA thalassemia carriers had been reported. Herein, we reported two cases of -&#945;3.7/--SEA thalassemia with the headache and elevated bilirubin respectively.</p></sec><sec id="Sec2"><title>Results</title><sec id="Sec3"><title>Case report</title><p id="Par6">A 42-year-old woman was admitted to the hospital with intermittent headaches for 5 years. The patient declared that she had recurrent headache with a tightness feeling on the head for nearly half a month, without eye distension, nausea, vomiting, palpitation, chest tightness, abdominal pain, diarrhea. The patient had a history of caesarean section with blood transfusion. The neurologist ordered MRA and MRV of the head and plain scans of the head and cervical spine, and detected a few demyelinating lesions in the brain, abnormal signals in the Subcutaneous region of the bilateral frontal face, and degenerative lesions in the cervical spine, but no evident stenosis of cerebral arteries and abnormality of cranial MRV. The abnormal indicators in routine blood tests were Hematokrit 28.90% (reference: 35&#8211;45), mean corpuscular volume 60.4 fL (reference: 82&#8211;100), mean corpuscular hemoglobin 17.5 pg (reference: 27&#8211;34), mean hemoglobin concentration 290.00&#160;g/L (reference: 316&#8211;354), red blood cell distribution width-coefficient of variation 22.3% (reference: 11.5&#8211;14.5), red blood cell distribution width standard deviation 48.7 fL (reference: 39&#8211;46), platelet distribution width 14.40% (reference: 15&#8211;17), hemoglobin concentration 84&#160;g/L (reference: 115&#8211;150), indicating the potential microcytic hypochromic anemia (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par7">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Abnormallaboratory indicators during hospitalization of the first case</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Results</th><th align="left" colspan="1" rowspan="1">Normal range</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Hematokrit, %</td><td align="left" colspan="1" rowspan="1">28.90</td><td align="left" colspan="1" rowspan="1">35&#8211;45</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean corpuscular volume, fL</td><td align="left" colspan="1" rowspan="1">60.4</td><td align="left" colspan="1" rowspan="1">82&#8211;100</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean corpuscular hemoglobin, pg</td><td align="left" colspan="1" rowspan="1">17.5</td><td align="left" colspan="1" rowspan="1">27&#8211;34</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean hemoglobin concentration, g/L</td><td align="left" colspan="1" rowspan="1">290.00</td><td align="left" colspan="1" rowspan="1">316&#8211;354</td></tr><tr><td align="left" colspan="1" rowspan="1">Red blood cell distribution width - coefficient of variation, %</td><td align="left" colspan="1" rowspan="1">22.3</td><td align="left" colspan="1" rowspan="1">11.5&#8211;14.5</td></tr><tr><td align="left" colspan="1" rowspan="1">Red blood cell distribution width standard deviation, fL</td><td align="left" colspan="1" rowspan="1">48.7</td><td align="left" colspan="1" rowspan="1">39&#8211;46</td></tr><tr><td align="left" colspan="1" rowspan="1">Platelet distribution width, %</td><td align="left" colspan="1" rowspan="1">14.40</td><td align="left" colspan="1" rowspan="1">15&#8211;17</td></tr><tr><td align="left" colspan="1" rowspan="1">Hemoglobin concentration, g/L</td><td align="left" colspan="1" rowspan="1">84</td><td align="left" colspan="1" rowspan="1">115&#8211;150</td></tr></tbody></table></table-wrap>
</p><p id="Par8">Peripheral blood cells smear displayed that the mature red blood cells were markedly different in size, with enlarged central pale area, occasional oval red blood cells and teardrop shaped red blood cells (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>A). The morphology and number of white blood cells were normal. After the consultation with the hematology department, the patient was screened for anemia. Elevated ferritin of 507.24 ng/mL (reference: 12&#8211;135) and erythropoietin of 41.49 mIU/mL (reference: 2.6&#8211;19), and no folate and vitamin B12 deficiency were observed, suggesting the possibility of thalassemia (Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>). Compared with the normal result as shown in Supplementary Fig. <xref rid="MOESM4" ref-type="media">1</xref>&#8201;A, the hemoglobin electrophoresis of the patient displayed the lower HbA2 level, indicating the &#945;-thalassemia or &#948;-thalassemia (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>B). Further reverse dot blot hybridization&#8194;assay was performed to identify the mutation and deletion of the globin genes. The probe distribution was shown in Supplementary Table <xref rid="MOESM2" ref-type="media">2</xref>. Compared with the normal result as shown in Supplementary Fig.&#160;<xref rid="MOESM4" ref-type="media">1</xref>B, the reverse dot blot hybridization&#8194;assay of the patient detected the dot positive for -&#945;3.7 and --SEA deletions, suggesting the -&#945;3.7/--SEA thalassemia (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>C). During hospitalization, the patient received subcutaneous erythropoietin three times a week, and took Yixuesheng capsules orally which contained multiple active ingredients including Ejiao, Lurong, Hongshen, Huangqi, Danggui and Fuling. After symptomatic and supportive treatment, the patient&#8217;s headache was significantly relieved and stable.</p><p id="Par9">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>The clinical results of the first case. (<bold>A</bold>) The peripheral blood cells smear assay. (<bold>B</bold>) The Hemoglobin electrophoresis assay. (<bold>C</bold>) The reverse dot blot hybridization&#8194;assay</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e345" position="float" orientation="portrait" xlink:href="277_2025_6607_Fig1_HTML.jpg"/></fig>
</p><p id="Par10">Another outpatient with gout and hypothyroidism history came to hematology department with elevated bilirubin for more than 30 years. The patient claimed that he had been seen at other hospital and considered as hereditary hemolytic anemia. Physical examination results during the previous year displayed that the patient&#8217;s hemoglobin was 100&#160;g/l (reference: 115&#8211;150), mean corpuscular volume 72.7 FL (reference: 82&#8211;100), total bilirubin 67.8 umol/l (reference: 3.4&#8211;17.1), and direct bilirubin 18.3 umol/l (reference: 0-6.8) (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). The liver function test in other hospital showed the total bilirubin 56.7 umol/l (reference: 3.4&#8211;17.1), indirect bilirubin 47.2 umol/l (reference: 0-6.8). The further examination in our hospital indicated the abnormal laboratory indicators of the hemoglobin concentration 105&#160;g/L (reference: 115&#8211;150), mean corpuscular volume 67.7 FL (reference: 82&#8211;100), uric acid 480 umol/l (reference: 150&#8211;416), total bilirubin 68.6 umol/l (reference: 3.4&#8211;17.1), direct bilirubin 7.4 umol/l (reference: 0-6.8), indirect bilirubin 61.2 umol/l (reference: 1.7&#8211;10.2) (Supplementary Table <xref rid="MOESM3" ref-type="media">3</xref>).</p><p id="Par11">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Abnormallaboratory indicators during hospitalization of the second case</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="left" colspan="1" rowspan="1">Results</th><th align="left" colspan="1" rowspan="1">Normal range</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">hemoglobin, g/l</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1">115&#8211;150</td></tr><tr><td align="left" colspan="1" rowspan="1">Mean corpuscular volume, fL</td><td align="left" colspan="1" rowspan="1">72.7</td><td align="left" colspan="1" rowspan="1">82&#8211;100</td></tr><tr><td align="left" colspan="1" rowspan="1">Total bilirubin, umol/l</td><td align="left" colspan="1" rowspan="1">67.8</td><td align="left" colspan="1" rowspan="1">3.4&#8211;17.1</td></tr><tr><td align="left" colspan="1" rowspan="1">Direct bilirubin, umol/l</td><td align="left" colspan="1" rowspan="1">18.3</td><td align="left" colspan="1" rowspan="1">0-6.8</td></tr></tbody></table></table-wrap>
</p><p id="Par12">The peripheral blood cell morphology examination was further improved, and it was found that the mature erythrocytes were different in size and small in size, the central pale staining area was enlarged, and oval erythrocytes, schiphocytes, and occasionally acanthocytes were seen (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>A). Other blood cell morphology showed no abnormal changes. Additionally, the reticulocyte count was elevated with the value of 7.52% (reference: 0.5&#8211;1.5), and the direct anti-human globulin C3 and direct anti-human globulin IgG were negative. Hemoglobin electrophoresis showed that the level of HbA2 was low (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>B). Reverse dot blot hybridization&#8194;assay identified the dot positive for -&#945;3.7 and --SEA deletions, suggesting the -&#945;3.7/--SEA thalassemia, and no special treatment was needed for the time being (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>C).</p><p id="Par13">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>The clinical results of the second case. (<bold>A</bold>) The peripheral blood cells smear assay. (<bold>B</bold>) The Hemoglobin electrophoresis assay. (<bold>C</bold>) The reverse dot blot hybridization&#8194;assay</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e433" position="float" orientation="portrait" xlink:href="277_2025_6607_Fig2_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec4"><title>Discussion</title><p id="Par14">&#945;-thalassemia is an autosomal recessive hereditary disease, caused by the deletion or functional defect of &#945;-globin gene. Impaired globin chain synthesis leads to an abnormal composition of hemoglobin (Hb) components, which in turn causes chronic hemolytic anemia. Southern China is a high incidence area of &#945;-thalassemia, especially in Guangdong, Guangxi, Hainan, Yunnan and Guizhou. Among them, the detection rate of &#945;-thalassemia in Guangdong is up to 8.3%. -&#945;3.7/--SEA thalassemia is a type of intermediate thalassemia, with the deletion of three &#945;-globin genes. Relative to common mild or quiescent thalassemia, the -&#945;3.7/--SEA thalassemiais relatively less distributes. In a study referring to 14,531 children with &#945;-thalassemia, the detection of -&#945;3.7/--SEA thalassemia was 5.91% [<xref ref-type="bibr" rid="CR7">7</xref>]. Although numerous studies have reported the diagnosis and clinical symptoms of &#945;-thalassemia [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], there are few studies reporting intermediate -&#945;3.7/--SEA thalassemia. Here, we had reported the diagnosis and clinical symptoms of two -&#945;3.7/--SEA thalassemia cases.</p><p id="Par15">The diagnosis of &#945;-thalassemia depends on the comprehensive consideration of clinical symptoms and laboratory test results [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. An important feature of thalassemia is microcytic hypochromic anemia, with the mean corpuscular volume (MCV)&#8201;&lt;&#8201;82&#160;fl. and mean corpuscular hemoglobin (MCH)&#8201;&lt;&#8201;27.0 Pg. In the first case, the MCV and MCH were significantly lower than the reference value with the values of 60.4 fL and 17.5 pg respectively, suggesting a typical microcytic hypochromic anemia. The blood cell morphology also strengthened this, in which the size of mature erythrocytes varied markedly, with enlarged central pale areas and occasional oval and teardrop-shaped erythrocytes. Further screening for ferritin observed no deficiency, suggesting the possibility of thalassemia. Simialr laboratory examination and blood cell morphology were also observed in the second case. The abnormal increase of HbA2 is one of the important evidence for the diagnosis of &#946;-thalassemia [<xref ref-type="bibr" rid="CR12">12</xref>]. In the two cases, HbA2 in hemoglobin electrophoresis was lower than the normal level, indicating the exclusion of &#946;-thalassemia. By the reverse dot blot hybridization&#8194;assay, we detected the deletions of &#945;3.7 and SEA in globin gene. In view of the -&#945;3.7/--SEA thalassemia diagnostic process in the two cases, the combined diagnosis of hematological examination, blood cell morphology and gene identification was effective and accurate.</p><p id="Par16">-&#945;3.7/--SEA thalassemia is a type of HbH disease in which the clinical manifestations vary greatly from no mild to moderate chronic anemia, and the time and severity of anemia are different [<xref ref-type="bibr" rid="CR13">13</xref>]. Carriers may have no symptoms at birth, but as they grow older, they may develop the clinical manifestations including hemolytic anemia, methemoglobinemia, fatigue and weakness, hepatosplenomegaly, and mild jaundice [<xref ref-type="bibr" rid="CR14">14</xref>]. Due to the prolonged anemia, carriers may developed several complications, including iron overload, infection, bone deformity, splenomegaly, growth retardation, hepatobiliary disease, and thrombosis [<xref ref-type="bibr" rid="CR15">15</xref>]. Here, the first patient suffered from chronic headaches. &#945;-thalassemia might be associated with headache. A recent study had reoprted the post-transfusion severe headache in a patient with thalassemia with superficial siderosis of the central nervous system [<xref ref-type="bibr" rid="CR16">16</xref>]. A possible reason was that cerebral hypoxia due to anemia might cause headache. In addition, other complications of thalassemia, such as iron overload and cardiac problems, might also indirectly cause headache. After ameliorative treatment for anemia, the patient&#8217;s headache was significantly relieved, suggesting the strong association between -&#945;3.7/--SEA thalassemia and headache. Although no history of blood transfusion for anemia, the extremely elevated ferritin of the patient suggested the potential risk of iron overload which might damage multiple tissues and organs. Further iron-lowering therapies might be necessary. Combined these observations, the patient exhibited a relatively moderate clinical manifestation of -&#945;3.7/--SEA thalassemia.</p><p id="Par17">The other patient presented with different symptoms and suffered from elevated bilirubin for many years. Bilirubin is a yellow pigment in the blood, mainly produced by the breakdown of old red blood cells [<xref ref-type="bibr" rid="CR17">17</xref>]. -&#945;3.7/--SEA thalassemia was a possible cause of abnormal bilirubin. Thalassemia could lead to shortened life span and increased destruction of red blood cells, the ongoing hemolysis increased the release of bilirubin, leading the perennial elevated bilirubin. Gilbert syndrome was another potential cause of the abnormal bilirubin, which was an inherited liver metabolism disorder caused by the defect of UGT1A1 gene, and characterized by increased unconjugated bilirubin in the blood [<xref ref-type="bibr" rid="CR18">18</xref>]. In this case, Gilbert syndrome and -&#945;3.7/--SEA thalassemia might coexist, jointly contributing to the elevated bilirubin levels. Although the patient underwent no further testing, it was essential for determining the etiology to screen for UGT1A1 gene mutations in both the patient and family members during future diagnostic evaluation. Besides, -&#945;3.7/--SEA thalassemia might be associated with the gout history caused by hyperuricemia. Patients with thalassemia had a high rate of cell turnover due to chronic hemolysis and ineffective erythropoiesis, possibly leading the anticipated hyperuricemia [<xref ref-type="bibr" rid="CR19">19</xref>]. A recent study reported that hyperuricemia was found in approximately 40% of patients with thalassemia, and gouty arthritis developed in 6% of patients [<xref ref-type="bibr" rid="CR19">19</xref>]. Further disease diagnosis and therapeutic effects are still required for verifying the relationship between gout and -&#945;3.7/--SEA thalassemia.</p><p id="Par18">This case report still has several limitations. First, the follow-up information for the inpatient needs to be further documented. The causal relationship between thalassemia and the clinical symptoms still requires additional follow-up data for verification. Furthermore, the other outpatient and their relatives should undergo testing for UGT1A1 gene mutations to investigate the potential risk of Gilbert&#8217;s syndrome. Lastly, subsequent thalassemia genetic sequencing would contribute to a better analysis of the type and characteristics of the thalassemia.</p></sec><sec id="Sec5"><title>Conclusion</title><p id="Par19">In this case report, we had reported the diagnosis and symptoms of two patients with intermediate -&#945;3.7/--SEA thalassemia. Comprehensive judgment of clinical symptoms and laboratory test results was applicative for -&#945;3.7/--SEA thalassemia diagnose. Long-term anemia might lead to diverse clinical symptoms and complications, which required more attention and early treatment.</p></sec><sec id="Sec7" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="277_2025_6607_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="277_2025_6607_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="277_2025_6607_MOESM3_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 3</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="277_2025_6607_MOESM4_ESM.jpg" position="float" orientation="portrait"><caption><p>Supplementary Material 4</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Xiuling Wang and Yu Ding are contributed equally to this work.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>X.W. and Y.D. wrote the manuscript and J.H. critically reviewed it. Z.H. followed the patient. All authors reviewed the manuscript and approved the submitted version.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by the Natural Science Foundation of China (82200922).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval</title><p id="Par20">This study was approved by the ethics committee of The Central Hospital of Wuhan, and the study was conducted in accordance with the local legislation and institutional requirements.</p></notes><notes id="FPar2"><title>Consent to publish</title><p id="Par21">The written inform&#160;consent&#160;for publication was obtained from the patients.</p></notes><notes id="FPar5" notes-type="COI-statement"><title>Competing interests</title><p id="Par22">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>JY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HF</given-names></name><name name-style="western"><surname>Tong</surname><given-names>JR</given-names></name><name name-style="western"><surname>Wei</surname><given-names>YN</given-names></name><name name-style="western"><surname>Huang</surname><given-names>LL</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L</given-names></name></person-group><article-title>Analysis of the anemia characteristics in early pregnancy and outcomes of pregnant women with hemoglobin H disease</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2023</year><volume>27</volume><issue>3</issue><fpage>1027</fpage><lpage>1032</lpage><pub-id pub-id-type="doi">10.26355/eurrev_202302_31198</pub-id><pub-id pub-id-type="pmid">36808349</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Su JY, Chen Y, Chen HF, Tong JR, Wei YN, Huang LL, Deng L (2023) Analysis of the anemia characteristics in early pregnancy and outcomes of pregnant women with hemoglobin H disease. Eur Rev Med Pharmacol Sci 27(3):1027&#8211;1032. 10.26355/eurrev_202302_31198<pub-id pub-id-type="pmid">36808349</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202302_31198</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuson</surname><given-names>ED</given-names></name><name name-style="western"><surname>Naranjo</surname><given-names>MLT</given-names></name></person-group><article-title>Thalassemia in the Philippines</article-title><source>Hemoglobin</source><year>2022</year><volume>46</volume><issue>1</issue><fpage>36</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1080/03630269.2021.2023566</pub-id><pub-id pub-id-type="pmid">35950581</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Yuson ED, Naranjo MLT (2022) Thalassemia in the Philippines. Hemoglobin 46(1):36&#8211;38. 10.1080/03630269.2021.2023566<pub-id pub-id-type="pmid">35950581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/03630269.2021.2023566</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merkeley</surname><given-names>H</given-names></name><name name-style="western"><surname>Bolster</surname><given-names>L</given-names></name></person-group><article-title>Thalassemia</article-title><source>Can Med Assoc J</source><year>2020</year><volume>192</volume><fpage>41E1210</fpage><pub-id pub-id-type="doi">10.1503/cmaj.191613</pub-id><pub-id pub-id-type="pmcid">PMC7588257</pub-id><pub-id pub-id-type="pmid">33051316</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Merkeley H, Bolster L (2020) Thalassemia. Can Med Assoc J 192:41E1210. 10.1503/cmaj.191613<pub-id pub-id-type="doi" assigning-authority="pmc">10.1503/cmaj.191613</pub-id><pub-id pub-id-type="pmcid">PMC7588257</pub-id><pub-id pub-id-type="pmid">33051316</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shafique</surname><given-names>F</given-names></name><name name-style="western"><surname>Ali</surname><given-names>S</given-names></name><name name-style="western"><surname>Almansouri</surname><given-names>T</given-names></name><name name-style="western"><surname>Van Eeden</surname><given-names>F</given-names></name><name name-style="western"><surname>Shafi</surname><given-names>N</given-names></name><name name-style="western"><surname>Khalid</surname><given-names>M</given-names></name><name name-style="western"><surname>Khawaja</surname><given-names>S</given-names></name><name name-style="western"><surname>Andleeb</surname><given-names>S</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>MU</given-names></name></person-group><article-title>Thalassemia, a human blood disorder</article-title><source>Brazilian J biology = Revista Brasleira De Biol</source><year>2021</year><volume>83</volume><fpage>e246062</fpage><pub-id pub-id-type="doi">10.1590/1519-6984.246062</pub-id><pub-id pub-id-type="pmid">34495151</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Shafique F, Ali S, Almansouri T, Van Eeden F, Shafi N, Khalid M, Khawaja S, Andleeb S, Hassan MU (2021) Thalassemia, a human blood disorder. Brazilian J biology = Revista Brasleira De Biol 83:e246062. 10.1590/1519-6984.246062<pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/1519-6984.246062</pub-id><pub-id pub-id-type="pmid">34495151</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruengdit</surname><given-names>C</given-names></name><name name-style="western"><surname>Punyamung</surname><given-names>M</given-names></name><name name-style="western"><surname>Maneewong</surname><given-names>K</given-names></name><name name-style="western"><surname>Khamphikham</surname><given-names>P</given-names></name><name name-style="western"><surname>Tepakhan</surname><given-names>W</given-names></name><name name-style="western"><surname>Pornprasert</surname><given-names>S</given-names></name></person-group><article-title>Characterization of hbh disease caused by compound heterozygotes &#945;(+)-thalassemia 3.7 kb deletion and a large novel &#945;(0)-thalassemia deletion</article-title><source>Hemoglobin</source><year>2025</year><volume>49</volume><issue>3</issue><fpage>229</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1080/03630269.2025.2495698</pub-id><pub-id pub-id-type="pmid">40325513</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Ruengdit C, Punyamung M, Maneewong K, Khamphikham P, Tepakhan W, Pornprasert S (2025) Characterization of hbh disease caused by compound heterozygotes &#945;(+)-thalassemia 3.7 kb deletion and a large novel &#945;(0)-thalassemia deletion. Hemoglobin 49(3):229&#8211;232. 10.1080/03630269.2025.2495698<pub-id pub-id-type="pmid">40325513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/03630269.2025.2495698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>YH</given-names></name><name name-style="western"><surname>Fan</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Pan</surname><given-names>ZW</given-names></name><name name-style="western"><surname>Song</surname><given-names>CL</given-names></name></person-group><article-title>[Spectrum of gene deletion in 471 children with &#945;-thalassemia]. Zhongguo Dang Dai Er Ke Za zhi&#8201;=&#8201;chinese</article-title><source>J Contemp Pediatr</source><year>2012</year><volume>14</volume><issue>4</issue><fpage>264</fpage><lpage>266</lpage><pub-id pub-id-type="pmid">22537953</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Lin YH, Fan L, Zhang Z, Pan ZW, Song CL (2012) [Spectrum of gene deletion in 471 children with &#945;-thalassemia]. Zhongguo Dang Dai Er Ke Za zhi&#8201;=&#8201;chinese. J Contemp Pediatr 14(4):264&#8211;266<pub-id pub-id-type="pmid">22537953</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>DM</given-names></name><name name-style="western"><surname>He</surname><given-names>S</given-names></name></person-group><article-title>Genotypes of thalassemia in children: an analysis of 30 417 cases. Zhongguo Dang Dai Er Ke Za zhi&#8201;=&#8201;chinese</article-title><source>J Contemp Pediatr</source><year>2021</year><volume>23</volume><issue>8</issue><fpage>841</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.7499/j.issn.1008-8830.2104035</pub-id><pub-id pub-id-type="pmcid">PMC8428907</pub-id><pub-id pub-id-type="pmid">34511175</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Li DM, He S (2021) Genotypes of thalassemia in children: an analysis of 30 417 cases. Zhongguo Dang Dai Er Ke Za zhi&#8201;=&#8201;chinese. J Contemp Pediatr 23(8):841&#8211;847. 10.7499/j.issn.1008-8830.2104035<pub-id pub-id-type="doi" assigning-authority="pmc">10.7499/j.issn.1008-8830.2104035</pub-id><pub-id pub-id-type="pmcid">PMC8428907</pub-id><pub-id pub-id-type="pmid">34511175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pata</surname><given-names>S</given-names></name><name name-style="western"><surname>Laopajon</surname><given-names>W</given-names></name><name name-style="western"><surname>Pongpaiboon</surname><given-names>M</given-names></name><name name-style="western"><surname>Thongkum</surname><given-names>W</given-names></name><name name-style="western"><surname>Polpong</surname><given-names>N</given-names></name><name name-style="western"><surname>Munkongdee</surname><given-names>T</given-names></name><name name-style="western"><surname>Paiboonsukwong</surname><given-names>K</given-names></name><name name-style="western"><surname>Fucharoen</surname><given-names>S</given-names></name><name name-style="western"><surname>Tayapiwatana</surname><given-names>C</given-names></name><name name-style="western"><surname>Kasinrerk</surname><given-names>W</given-names></name></person-group><article-title>Impact of the detection of &#950;-globin chains and hemoglobin bart&#8217;s using immunochromatographic strip tests for &#945;0-thalassemia (-SEA) differential diagnosis</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><issue>10</issue><fpage>e0223996</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0223996</pub-id><pub-id pub-id-type="pmid">31661492</pub-id><pub-id pub-id-type="pmcid">PMC6818768</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Pata S, Laopajon W, Pongpaiboon M, Thongkum W, Polpong N, Munkongdee T, Paiboonsukwong K, Fucharoen S, Tayapiwatana C, Kasinrerk W (2019) Impact of the detection of &#950;-globin chains and hemoglobin bart&#8217;s using immunochromatographic strip tests for &#945;0-thalassemia (-SEA) differential diagnosis. PLoS ONE 14(10):e0223996. 10.1371/journal.pone.0223996<pub-id pub-id-type="pmid">31661492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0223996</pub-id><pub-id pub-id-type="pmcid">PMC6818768</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>T</given-names></name></person-group><article-title>Next-generation sequencing analysis of the molecular spectrum of thalassemia in southern Jiangxi, China</article-title><source>Hum Genomics</source><year>2023</year><volume>17</volume><issue>1</issue><fpage>77</fpage><pub-id pub-id-type="doi">10.1186/s40246-023-00520-5</pub-id><pub-id pub-id-type="pmid">37592328</pub-id><pub-id pub-id-type="pmcid">PMC10436446</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Yang T, Luo X, Liu Y, Lin M, Zhao Q, Zhang W, Chen Z, Dong M, Wang J, Wang Q, Zhang X, Zhong T (2023) Next-generation sequencing analysis of the molecular spectrum of thalassemia in southern Jiangxi, China. Hum Genomics 17(1):77. 10.1186/s40246-023-00520-5<pub-id pub-id-type="pmid">37592328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40246-023-00520-5</pub-id><pub-id pub-id-type="pmcid">PMC10436446</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mensah</surname><given-names>C</given-names></name><name name-style="western"><surname>Sheth</surname><given-names>S</given-names></name></person-group><article-title>Optimal strategies for carrier screening and prenatal diagnosis of &#945;- and &#946;-thalassemia</article-title><source>Hematology</source><year>2021</year><volume>2021</volume><issue>1</issue><fpage>607</fpage><lpage>613</lpage><pub-id pub-id-type="doi">10.1182/hematology.2021000296</pub-id><pub-id pub-id-type="pmid">34889395</pub-id><pub-id pub-id-type="pmcid">PMC8791174</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Mensah C, Sheth S (2021) Optimal strategies for carrier screening and prenatal diagnosis of &#945;- and &#946;-thalassemia. Hematology 2021(1):607&#8211;613. 10.1182/hematology.2021000296<pub-id pub-id-type="pmid">34889395</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/hematology.2021000296</pub-id><pub-id pub-id-type="pmcid">PMC8791174</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Musallam</surname><given-names>KM</given-names></name><name name-style="western"><surname>Lombard</surname><given-names>L</given-names></name><name name-style="western"><surname>Kistler</surname><given-names>KD</given-names></name><name name-style="western"><surname>Arregui</surname><given-names>M</given-names></name><name name-style="western"><surname>Gilroy</surname><given-names>KS</given-names></name><name name-style="western"><surname>Chamberlain</surname><given-names>C</given-names></name><name name-style="western"><surname>Zagadailov</surname><given-names>E</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>K</given-names></name><name name-style="western"><surname>Taher</surname><given-names>AT</given-names></name></person-group><article-title>Epidemiology of clinically significant forms of alpha- and beta-thalassemia: a global map of evidence and gaps</article-title><source>Am J Hematol</source><year>2023</year><volume>98</volume><issue>9</issue><fpage>1436</fpage><lpage>1451</lpage><pub-id pub-id-type="doi">10.1002/ajh.27006</pub-id><pub-id pub-id-type="pmid">37357829</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Musallam KM, Lombard L, Kistler KD, Arregui M, Gilroy KS, Chamberlain C, Zagadailov E, Ruiz K, Taher AT (2023) Epidemiology of clinically significant forms of alpha- and beta-thalassemia: a global map of evidence and gaps. Am J Hematol 98(9):1436&#8211;1451. 10.1002/ajh.27006<pub-id pub-id-type="pmid">37357829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ajh.27006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Almomani</surname><given-names>AA</given-names></name><name name-style="western"><surname>Shraim</surname><given-names>AS</given-names></name><name name-style="western"><surname>Atoom</surname><given-names>AM</given-names></name><name name-style="western"><surname>Abdel</surname><given-names>MBA</given-names></name><name name-style="western"><surname>Alhmoud</surname><given-names>JF</given-names></name></person-group><article-title>Evaluation of the validity of the pre-marriage mean corpuscular volume value as a predictive test for b-thalassemia carrier status</article-title><source>J Med Biochem</source><year>2023</year><volume>42</volume><issue>2</issue><fpage>195</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.5937/jomb0-37682</pub-id><pub-id pub-id-type="pmid">36987417</pub-id><pub-id pub-id-type="pmcid">PMC10040200</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Almomani AA, Shraim AS, Atoom AM, Abdel MBA, Alhmoud JF (2023) Evaluation of the validity of the pre-marriage mean corpuscular volume value as a predictive test for b-thalassemia carrier status. J Med Biochem 42(2):195&#8211;205. 10.5937/jomb0-37682<pub-id pub-id-type="pmid">36987417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5937/jomb0-37682</pub-id><pub-id pub-id-type="pmcid">PMC10040200</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shamoon</surname><given-names>RP</given-names></name><name name-style="western"><surname>Yassin</surname><given-names>AK</given-names></name><name name-style="western"><surname>Polus</surname><given-names>RK</given-names></name><name name-style="western"><surname>Ali</surname><given-names>MD</given-names></name></person-group><article-title>Genotype-phenotype correlation of hbh disease in Northern Iraq</article-title><source>BMC Med Genet</source><year>2020</year><volume>21</volume><issue>1</issue><fpage>203</fpage><pub-id pub-id-type="doi">10.1186/s12881-020-01141-8</pub-id><pub-id pub-id-type="pmid">33059634</pub-id><pub-id pub-id-type="pmcid">PMC7559146</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Shamoon RP, Yassin AK, Polus RK, Ali MD (2020) Genotype-phenotype correlation of hbh disease in Northern Iraq. BMC Med Genet 21(1):203. 10.1186/s12881-020-01141-8<pub-id pub-id-type="pmid">33059634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12881-020-01141-8</pub-id><pub-id pub-id-type="pmcid">PMC7559146</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Harewood J, Azevedo AM (2025)&#160;Alpha Thalassemia. In: StatPearls [Internet]. StatPearls Publishing Copyright &#169; 2025, StatPearls Publishing LLC., Treasure Island (FL) ineligible companies. Disclosure: Alexandre Azevedo declares no relevant financial relationships with ineligible companies<pub-id pub-id-type="pmid">28722856</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>V</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>P</given-names></name></person-group><article-title>Complications in transfusion-dependent thalassemia</article-title><source>Indian Pediatr</source><year>2022</year><volume>59</volume><issue>12</issue><fpage>911</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1007/s13312-022-2660-9</pub-id><pub-id pub-id-type="pmid">36511205</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Gupta V, Aggarwal P (2022) Complications in transfusion-dependent thalassemia. Indian Pediatr 59(12):911&#8211;912<pub-id pub-id-type="pmid">36511205</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name></person-group><article-title>Post-transfusion severe headache in a patient with thalassemia with superficial siderosis of the central nervous system: a case report and literature review</article-title><source>BMC Neurol</source><year>2024</year><volume>24</volume><issue>1</issue><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/s12883-024-03526-1</pub-id><pub-id pub-id-type="pmid">38184518</pub-id><pub-id pub-id-type="pmcid">PMC10770896</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Liu X, Jiang H, Ren L, Cao L (2024) Post-transfusion severe headache in a patient with thalassemia with superficial siderosis of the central nervous system: a case report and literature review. BMC Neurol 24(1):21. 10.1186/s12883-024-03526-1<pub-id pub-id-type="pmid">38184518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12883-024-03526-1</pub-id><pub-id pub-id-type="pmcid">PMC10770896</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vitek</surname><given-names>L</given-names></name><name name-style="western"><surname>Hinds</surname><given-names>TD</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Stec</surname><given-names>DE</given-names></name><name name-style="western"><surname>Tiribelli</surname><given-names>C</given-names></name></person-group><article-title>The physiology of bilirubin: health and disease equilibrium</article-title><source>Trends Mol Med</source><year>2023</year><volume>29</volume><issue>4</issue><fpage>315</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2023.01.007</pub-id><pub-id pub-id-type="pmid">36828710</pub-id><pub-id pub-id-type="pmcid">PMC10023336</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Vitek L, Hinds TD Jr., Stec DE, Tiribelli C (2023) The physiology of bilirubin: health and disease equilibrium. Trends Mol Med 29(4):315&#8211;328. 10.1016/j.molmed.2023.01.007<pub-id pub-id-type="pmid">36828710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molmed.2023.01.007</pub-id><pub-id pub-id-type="pmcid">PMC10023336</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>V&#237;tek</surname><given-names>L</given-names></name><name name-style="western"><surname>Tiribelli</surname><given-names>C</given-names></name></person-group><article-title>Gilbert&#8217;s syndrome revisited</article-title><source>J Hepatol</source><year>2023</year><volume>79</volume><issue>4</issue><fpage>1049</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2023.06.004</pub-id><pub-id pub-id-type="pmid">37390966</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">V&#237;tek L, Tiribelli C (2023) Gilbert&#8217;s syndrome revisited. J Hepatol 79(4):1049&#8211;1055. 10.1016/j.jhep.2023.06.004<pub-id pub-id-type="pmid">37390966</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2023.06.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaloemwong</surname><given-names>J</given-names></name><name name-style="western"><surname>Tantiworawit</surname><given-names>A</given-names></name><name name-style="western"><surname>Rattanathammethee</surname><given-names>T</given-names></name><name name-style="western"><surname>Chai-Adisaksopha</surname><given-names>C</given-names></name><name name-style="western"><surname>Rattarittamrong</surname><given-names>E</given-names></name><name name-style="western"><surname>Norasetthada</surname><given-names>L</given-names></name><name name-style="western"><surname>Charoenkwan</surname><given-names>P</given-names></name><name name-style="western"><surname>Louthrenoo</surname><given-names>W</given-names></name></person-group><article-title>Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients</article-title><source>Ann Hematol</source><year>2019</year><volume>98</volume><issue>5</issue><fpage>1101</fpage><lpage>1110</lpage><pub-id pub-id-type="doi">10.1007/s00277-019-03630-0</pub-id><pub-id pub-id-type="pmid">30721337</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Chaloemwong J, Tantiworawit A, Rattanathammethee T, Chai-Adisaksopha C, Rattarittamrong E, Norasetthada L, Charoenkwan P, Louthrenoo W (2019) Hyperuricemia, urine uric excretion, and associated complications in thalassemia patients. Ann Hematol 98(5):1101&#8211;1110. 10.1007/s00277-019-03630-0<pub-id pub-id-type="pmid">30721337</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00277-019-03630-0</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>